Skip to main content
. 2021 Dec 8;10(12):1587. doi: 10.3390/pathogens10121587

Table 1.

Baseline demographic and clinical characteristics of study participants, 2017–2020 a.

Total Number of Observations b
n = 6661		 With PDR to Any Drug c,d
n = 957		 p Value With PDR to EFV/NVP d
n = 690		 p Value
Gender, n (%)
Cisgender Women
Cisgender Men
Transgender Women
Transgender Men
Missing
267 (4.0)
6234 (93.6)
51 (0.8)
3 (0.0)
106 (1.6)
32 (12.0)
907 (14.5)
6 (11.8)
0 (0.0)
12 (11.3)
0.14
0.06
0.39
0.62
0.23
24 (9.0)
653 (10.5)
4 (7.8)
0 (0.0)
9 (8.5)
0.26
0.13
0.38
0.72
0.33
Age (years) e
Median (IQR)
28 (24–35)
28 (24–34)
0.09
28 (24–34)
0.30
State of residence, n (%)
Mexico City
Mexico State
Other
Missing
4223 (63.4)
967 (14.5)
90 (1.4)
1381 (20.7)
621 (14.7)
142 (14.7)
9 (10.0)
185 (13.4)
0.16
0.40
0.15
0.13
448 (10.6)
107 (11.1)
5 (5.6)
130 (9.4)
0.20
0.23
0.08
0.10
HIV subtype, n (%)
B
Non-B
6577 (98.7)
84 (1.3)
946 (14.4)
11 (13.1)
0.44
680 (11.6)
10 (11.9)
0.37
Viral load (log RNA copies/mL) f
Median (range)
4.8 (4.25–5–31)
4.7 (4.2–5.3)
0.02 *
4.7 (4.2–5.3)
0.03 *
CD4+ T cell count (cells/mm3), n g
Median (IQR)
249 (120–395)
250 (123–407)
0.22
254 (129–405)
0.16
CD4+ T cell count category, n (%)
<200 cells/mm3
200–500 cells/mm3
>500 cells/mm3
Missing
2323 (34.87)
2721 (40.8)
809 (12.2)
808 (12.1)
334 (14.4)
389 (14.3)
129 (15.9)
105 (13.0)
0.51
0.46
0.10
0.13
240 (10.3)
285 (10.5)
94 (11.6)
71 (8.8)
0.50
0.41
0.12
0.06
CD4+ T cell %, n h
Median (IQR)
15 (9–21)
15 (9–22)
0.27
15 (10–22)
0.14

a Data for 6661 participants enrolled from January 2017 to December 2020. b Column percentages are shown. c Using the WHO definition for PDR (see Methods). d Row percentages are shown. e Data missing for 114 participants (n = 6547). f Data missing for 557 participants (n = 6104). g Data missing for 808 participants (n = 5853). h Data missing for 2234 participants (n = 4427). * p < 0.05. PDR; pretreatment drug resistance; EFV, efavirenz; NVP, nevirapine; IQR, interquartile range.